drugset / Trial / NCT06892054

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

NCT06892054

NaSingle-groupOpen-labelTreatment

Summary

The main objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma harboring KRAS p.G12C mutation.

Timeline

Start
2025-08-08
Primary completion
2030-08-08
Completion
2030-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotorasib Small molecule 960 mg Oral